AzarGen Biotechnologies Overview
- Founded
- 2003
- Status
- Private
- Employees
- 5
- Latest Deal Type
- Series B
- Latest Deal Amount
- $3.1M
- Investors
- 2
AzarGen Biotechnologies General Information
Description
Developer of human therapeutic proteins designed to increase the survivability of premature-born infants. The company's human therapeutic proteins are made using advanced plant-based genetic engineering and synthetic biology techniques and it also offers a plant based expression technology which comprises optimal combinations of novel synthetic promoters, combined with enhancer and purification components, enabling medical professionals to offers drugs with superior clinical efficacy at low cost that can significantly improve the health status of citizens.
Contact Information
Primary Industry
Other Healthcare Technology Systems
Other Industries
Social/Platform Software
Biotechnology
Primary Office
- Natural Science Building, Room 2066
- Merriman Avenue, Stellenbosch
- Cape Town
- South Africa
+27 021 000 0000
AzarGen Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Angel (individual) | 07-Jan-2016 | $3.1M | 00.00 | Completed | Startup | |
| 1. Seed Round | Completed | Startup |
AzarGen Biotechnologies Executive Team (2)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Mauritz Venter Ph.D | Co-Founder & Chief Executive Officer | ||
| Cobus Zwiegelaar Ph.D | Co-Founder, Chief-Scientist & Chief Operating Officer |
AzarGen Biotechnologies Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial